A Possible Cluster of AEFI (Adverse Event Following Vaccination) Following AZD1222 (Covishield) Vaccination in India?

 Abstract

In order to mitigate the spread of the COVID-19 infection in India, the Indian government granted approval for the emergency use of Oxford-AstraZeneca’s COVID-19 (coronavirus disease 2019) vaccine AZD1222 (Covishield). The biggest large-scale COVID-19 vaccination drive in the world is being carried out continuously till date in India. In this research article, a possible cluster of AEFI (Adverse Event Following Vaccination) following AZD1222 (Covishield) vaccination in India has been briefly presented.

Read more about this article: https://juniperpublishers.com/ijoprs/IJOPRS.MS.ID.555676.php

Read more Juniper Publishers Google Scholar Articles: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=Y8LS2LwAAAAJ&citation_for_view=Y8LS2LwAAAAJ:70eg2SAEIzsC

 

Comments

Popular posts from this blog

Juniper Publishers 2025 Journal Categories Explained: Medicine, Biology, Engineering & More Introduction

Application of a Real-Time Dashboard to Reduce Ventilator-Associated Pneumonia in Intensive Care Units

Deadly High Altitude Pulmonary Disorders: Acute Mountain Sickness (AMS); High Altitude Pulmonary Edema (HAPE) and High Altitude Cerebral Edema (HACE): A Clinical Review